It is radioactively labelled and thus visualizes the cancer cells during a PET scan. The health-related ... for which an effective therapy is available (Lutetium-177). By linking diagnostics ...

It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177 Lu)lutetium vipivotide ...

Hormone therapy, a treatment to stop ... to determine if people are eligible for PSMA lutetium-177 treatment. Before undergoing this type of scan, you receive an IV injection of another ...

68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177 Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease ...

This is the hope behind a radioactive molecule for targeted radionuclide therapy that has been developed at PSI and is now being tested ... more effective at treating cancer than a similar ...

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of province's cancer ...

Lu-177, for instance, can be paired with targeted drugs to locate and eradicate cancer cells effectively. Lu-177 is particularly important in peptide receptor radionuclide therapy (PRRT). Since it ...